anagliptin   Click here for help

GtoPdb Ligand ID: 11582

Synonyms: compound 4a [PMID: 22019046] | CWP-403 | SK-0403 | SK0403 | Suiny®
Approved drug PDB Ligand
anagliptin is an approved drug (Japan (2012))
Compound class: Synthetic organic
Comment: Anagliptin (SkK-0403) is a dipeptidyl peptidase-4 (DPP4) inhibitor [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 115.42
Molecular weight 383.21
XLogP 0.03
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#C[C@@H]1CCCN1C(=O)CNC(CNC(=O)c1cnc2n(c1)nc(c2)C)(C)C
Isomeric SMILES N#C[C@@H]1CCCN1C(=O)CNC(CNC(=O)c1cnc2n(c1)nc(c2)C)(C)C
InChI InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Anagliptin is approved in Japan and is used in the treatment of type 2 diabetes [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00532506 Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus Phase 2 Interventional Sanwa Kagaku Kenkyusho Co., Ltd.
NCT01169090 A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy Phase 2 Interventional Kowa Research Institute, Inc.
NCT01131091 A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403 Phase 1 Interventional Kowa Research Institute, Inc.
NCT01529541 Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone Phase 3 Interventional JW Pharmaceutical
NCT01529528 A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients Phase 3 Interventional JW Pharmaceutical